Clinical trials: Proof of Concept
Diabetes Mellitus, Type 2
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
- Trial name
- NCT00853151
- Testing
- LY2428757, TT223
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Solar Lentigo
Tolerance and Mode of Administration of Cyto-selective Cryotherapy Treatments in Face Brown Spots: Proof of Concept
Solar lentigos or lentigines are harmless patch of darkened skin, of different sizes and colors, due to the exposure to UV radiation. They are very common, especially in people over the age of 40 years old.
- Trial name
- AGILE2 (NCT05203263)
- Testing
- (810A-v1) device prototype, (810B-v1) device prototype, (810C-v1) device prototype
- Where
- Ukraine
- Volunteers
- 23 people
- Sponsor
- Cryonove Pharma
Netherton Syndrome
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12…
- Trial name
- NCT06137157
- Testing
- ATR12-351
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Azitra Inc.
Myopia, Astigmatism
Study of a Phakic Implantable Collamer Lens (ICL)
A prospective, open-labeled, single-site study of a phakic implantable collamer lens (ICL) for the correction/reduction of myopia with or without astigmatism.
- Trial name
- NCT07790965
- Testing
- Phakic Implantable Collamer Lens (ICL)
- Volunteers
- 10 people
- Sponsor
- Staar Surgical Company
Fibromyalgia Syndrome
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
- Trial name
- NCT00401830
- Testing
- Lacosamide
- Where
- 25 sites in United States
- Volunteers
- 159 people
- Sponsor
- UCB Pharma
Hypertrophic Scar
Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery
Phase 2a, prospective, randomized, double-blind, intra-subject, placebo-controlled, proof of concept study. Approximately twenty subjects will be randomized 1:1 to one of two treatment arms: Arm A: 2.0 mg/cm OLX10010 biweekly…
- Trial name
- NCT04877756
- Testing
- OLX10010
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Olix Pharmaceuticals, Inc.
Obstructive Sleep Apnea
Evaluation of the Restera™ Serene™ System in Adults With Obstructive Sleep Apnea
The purpose of this multi-center proof-of-concept safety and efficacy study is to collect chronic sleep-related data following percutaneous placement of electrode arrays near the hypoglossal nerve and the ansa cervicalis in…
- Trial name
- REST-HGN+AC (NCT07303452)
- Testing
- Neurostimulation
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Restera, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Anxiety Disorder
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
- Trial name
- NCT00616655
- Testing
- eszopiclone
- Where
- 57 sites in United States
- Volunteers
- 456 people
- Sponsor
- Sumitomo Pharma America, Inc.
Lentigo Solar
Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots PROOF OF CONCEPT
CRYO (N° 21D588A0001) study aims to evaluate the tolerance and adjust the mode of administration of a cyto-selective difluoroethane-based cryotherapy in the treatment of brown spots.
- Trial name
- CRYO-EC4 (NCT05014321)
- Testing
- EC16 medical device (CE marked), device prototype (810A-v1), device prototype (810B-v1)
- Where
- Ukraine
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cryonove Pharma
Obese
A Study of Distal Jejunal-release Dextrose in Obese Participants
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.
- Trial name
- NCT05385978
- Testing
- APHD-012, APHD-012P
- Where
- 9 sites in Georgia, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Aphaia Pharma US LLC
Infertility Implantation Failure
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure
The primary objective of the study was to provide further clinical and statistical evidence of the efficacy of r-hLIF, in comparison with placebo, administered during the luteal phase after IVF and ET for improving embryo…
- Trial name
- NCT00504608
- Testing
- Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic…
- Trial name
- NCT02781584
- Testing
- SEL, FIR, CILO
- Where
- 13 sites in United States, New Zealand
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Parkinson's Disease Dementia (PDD)
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already treated with a stable dose of a…
- Trial name
- SYNAPSE (NCT02258152)
- Testing
- SYN120
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Biotie Therapies Inc.
Degenerative Lumbar Spondylolisthesis
Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis
Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.
- Trial name
- NCT05961956
- Testing
- NVDX3
- Where
- Luxembourg
- Volunteers
- 5 people
- Sponsor
- Novadip Biosciences
Kidney Disease, Chronic
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
This randomized, single-blind, proof-of-concept study will investigate the protective effects of early treatment with Mircera in participants with chronic kidney disease on renal disease progression.
- Trial name
- NCT01194154
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 33 sites in Germany
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Intracerebral Hemorrhage
A Proof of Concept Study to Evaluate CN-105 in ICH Patients
A multicenter, open-label phase 2a trial of CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). Patients will be evaluated for eligibility within 12 hours of symptom onset.
- Trial name
- CATCH (NCT03168581)
- Testing
- CN-105
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- AegisCN LLC
Soft Tissue Mass Removal
Extraction of Stromal Vascular Fraction and Stem Cells From Fat Tissue
Human Adipose Tissue is considered as a new source for Stromal Stem Cells and offers a large therapeutic potential for many rare and common diseases that impacts millions of patients worldwide.
- Trial name
- NCT01399307
- Testing
- Liposuction
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Antria